Literature DB >> 11151398

Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and Ministry of Health perspective.

A O Wai1, L Frighetto, C A Marra, E Chan, P J Jewesson.   

Abstract

BACKGROUND: Outpatient parenteral antibiotic therapy (OPAT) programmes have become prevalent over the past 2 decades. From the US perspective, these programmes have been shown to reduce healthcare costs. No comprehensive analysis has been published from the Canadian perspective.
OBJECTIVE: To describe a Canadian OPAT programme for the 3-year period since its inception and to conduct a treatment cost analysis. DESIGN AND METHODS: Demographics and resource utilisation data (health professional labour, laboratory and diagnostic tests, antimicrobials, delivery, home nursing care, catheters and catheter placement) were prospectively collected for enrollees in the OPAT programme over the evaluation period. Avoided hospital resource utilisation was estimated via retrospective chart review by the investigators. Costs were retrospectively assigned to each resource and total cost avoidance by the OPAT programme was determined from each perspective. PERSPECTIVE: A teaching hospital and a provincial Ministry of Health (MOH). MAIN OUTCOME MEASURES AND
RESULTS: 140 treatment courses were initiated for 117 adult patients (mean age 54 years) who were enrolled into the programme. Mean pre-OPAT length of hospital stay was 12 days, and mean OPAT duration was 22.5 days. Bone/joint (39%), skin and soft tissue (16%), cardiac (13%) and respiratory tract (12%) infections were the most common infections managed. The most commonly used antimicrobials were vancomycin (29%), cloxacillin +/- gentamicin (22%) and ceftriaxone +/- gentamicin (11%) 85% of enrollees successfully completed their planned antimicrobial treatment regimens. Premature discontinuation of antimicrobial therapy for various reasons occurred in the remaining 15% of courses. The mean cost per treatment course of OPAT was 1910 Canadian dollars ($Can) from the hospital perspective and $Can6326 from the MOH perspective. Assuming that patients would have otherwise completed their antimicrobial therapy in hospital, the mean cost per treatment course was estimated to be $Can14,271. The overall cost avoidance of the OPAT programme was $Can1,730,520 (hospital perspective) and $Can1,009,450 (MOH perspective) over the 3-year assessment period. Sensitivity analyses revealed the results to be robust to plausible changes.
CONCLUSIONS: This analysis supports the premise that an adult OPAT programme can substantially reduce healthcare costs in the Canadian healthcare setting.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11151398     DOI: 10.2165/00019053-200018050-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

Review 1.  Economics of home intravenous services.

Authors:  N D Thickson
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

2.  Cost-effectiveness issues for home i.v. therapy in the United States.

Authors:  R Allen
Journal:  Hosp Formul       Date:  1993-01

3.  Treating bone and joint infections with teicoplanin: hospitalization vs outpatient cost issues.

Authors:  P C Craven
Journal:  Hosp Formul       Date:  1993-01

Review 4.  Home intravenous antibiotic therapy.

Authors:  D M Poretz
Journal:  Clin Geriatr Med       Date:  1991-11       Impact factor: 3.076

5.  Home intravenous antibiotic therapy. A safe and effective alternative to inpatient care.

Authors:  M L Grayson; J Silvers; J Turnidge
Journal:  Med J Aust       Date:  1995-03-06       Impact factor: 7.738

6.  Safety, efficacy, and cost savings in an outpatient intravenous antibiotic program.

Authors:  D N Williams; D Bosch; J Boots; J Schneider
Journal:  Clin Ther       Date:  1993 Jan-Feb       Impact factor: 3.393

7.  A review of the Manitoba home i.v. antibiotic program.

Authors:  D Cote; J Oruck; N Thickson
Journal:  Can J Hosp Pharm       Date:  1989-08

Review 8.  Experience with a physician-directed, clinic-based program for outpatient parenteral antibiotic therapy in the USA.

Authors:  A D Tice
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

9.  Cost analysis of a home intravenous antibiotic program.

Authors:  T M Chamberlain; M E Lehman; M J Groh; W P Munroe; T P Reinders
Journal:  Am J Hosp Pharm       Date:  1988-11

10.  Intravenous antibiotic therapy at home.

Authors:  H G Stiver; G O Telford; J M Mossey; D D Cote; E J van Middlesworth; S K Trosky; N L McKay; W L Mossey
Journal:  Ann Intern Med       Date:  1978-11       Impact factor: 25.391

View more
  15 in total

1.  A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus.

Authors:  Brent W Wieland; Jodie R Marcantoni; Kerry M Bommarito; David K Warren; Jonas Marschall
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

2.  Outpatient parenteral antimicrobial therapy.

Authors:  Kevin B Laupland; Louis Valiquette
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

3.  Hospital costs for patients with lower extremity cellulitis: a retrospective population-based study.

Authors:  Douglas Challener; Jasmine Marcelin; Sue Visscher; Larry Baddour
Journal:  Hosp Pract (1995)       Date:  2017-09-27

4.  Case files of the University of Massachusetts fellowship in medical toxicology: lethal dose of opioids contained in an elastomeric capsule labeled as vancomycin.

Authors:  James Courtney; Edward Boyer
Journal:  J Med Toxicol       Date:  2008-09

5.  Self-administered outpatient parenteral antimicrobial therapy: a report of three years experience in the Irish healthcare setting.

Authors:  J Kieran; A O'Reilly; J Parker; S Clarke; C Bergin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-08-21       Impact factor: 3.267

Review 6.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Outpatient parenteral antimicrobial therapy for surgery patients: A comparison with previous standard of care.

Authors:  Anjie Yang; Ron Fung; James Brunton; Linda Dresser
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

8.  Willingness to pay to assess patient preferences for therapy in a Canadian setting.

Authors:  Carlo A Marra; Luciana Frighetto; Alan F Goodfellow; Amy O Wai; M Lynn Chase; Ruth E Nicol; Carole A Leong; Sally Tomlinson; Barbara M Ferreira; Peter J Jewesson
Journal:  BMC Health Serv Res       Date:  2005-06-07       Impact factor: 2.655

9.  Outpatient Parenteral Antimicrobial Therapy in Pediatric Medicaid Enrollees.

Authors:  Jennifer L Goldman; Troy Richardson; Jason G Newland; Brian Lee; Jeffrey S Gerber; Matt Hall; Matthew Kronman; Adam L Hersh
Journal:  J Pediatric Infect Dis Soc       Date:  2017-03-01       Impact factor: 3.164

10.  Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy.

Authors:  Susan Rehm; Marilyn Campion; David E Katz; Rene Russo; Helen W Boucher
Journal:  J Antimicrob Chemother       Date:  2009-03-05       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.